View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 8, 2019

Medtronic’s HeartWare device reduces strokes in trial subjects

Medtronic has reported positive data from a retrospective analysis of the ENDURANCE and ENDURANCE Supplemental clinical trials.

Medtronic has reported positive data from a retrospective analysis of the ENDURANCE and ENDURANCE Supplemental clinical trials.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The studies were performed to assess the HeartWare HVAD System as a therapy for advanced heart failure patients that are not eligible for transplant. This left ventricular assist device (LVAD) is designed to increase the amount of blood circulating through a patient’s body.

According to the results of the trials, treatment with the HeartWare HVAD System led to a reduction in the number of strokes experienced by patients, including the occurrence of disabling strokes and stroke-related mortality.

Around 91% of participants in the HeartWare group stopped having strokes, with effects lasting for two years. Survival was found to be higher for patients that had experienced non-disabling strokes compared to those with disabling strokes.

“This analysis shows that stroke severity is an important determinant of outcomes.”

Compared to the subjects that received a control device, those in the HVAD pump arm tended to experience a lower stroke-related mortality rate.

Participants in the ENDURANCE Supplemental HVAD group experienced a 23% reduction in the total number of strokes, a 36% decrease in disabling strokes and a 39% reduction in stroke-related mortality, compared to patients in the ENDURANCE HVAD arm.

These findings have been presented at the 2019 International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions.

Stanford University medicine associate professor Jeffrey Teuteberg said: “This analysis shows that stroke severity is an important determinant of outcomes, and the use of the HVAD System with a guidelines-based blood pressure management strategy can, in addition to reducing overall stroke rates, reduce the occurrence of disabling stroke and improve survival in patients who experience strokes.”

Medtronic also launched the DT PAS and Apogee studies to validate the safety and effectiveness of the HeartWare device in a real-world setting.

The prospective, observational DT PAS study will monitor long-term, complication-free survival in 300 newly implanted destination therapy patients over two years at around 50 US sites. The study will track patients for up to five years.

Apogee is a multi-site study involving DT PAS patients interested in additional heart failure management protocol and data collection for one year.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network